NASDAQ:EXAS

Exact Sciences to Participate in June Investor Conferences

Retrieved on: 
Martedì, Maggio 28, 2024
General Health, Health, Oncology, Webcast, Conference

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

Key Points: 
  • Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
  • William Blair 44th Annual Growth Stock Conference, Chicago
    Goldman Sachs 45th Annual Global Healthcare Conference, Miami

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®

Retrieved on: 
Venerdì, Maggio 24, 2024
Oncology, Health, Health Technology, General Health, Research, Science, Patient, Survival, DNA, Recurrence, GGT, Docetaxel, Colorectal cancer, Sensitivity, Diagnosis, Exact sciences, Registry, Person, Breast cancer, Database, Neoplasm, Cancer, ASCO, CRC, Abstract, Mortality, Society, Breast, Cancer staging, Annual general meeting, Medical imaging

Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test in racially and ethnically diverse patients.

Key Points: 
  • Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test in racially and ethnically diverse patients.
  • “Exact Sciences’ growing evidence shows that earlier and more personalized treatment interventions lead to greater success for people living with cancer.
  • Therefore, effective cancer screening and diagnostic tools are critical to improving patient outcomes,” said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology at Exact Sciences.
  • “These data presented at ASCO support our goal to set new screening and diagnostic standards through rigorous innovation and real-world data collection across cancer care.

Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy

Retrieved on: 
Martedì, Maggio 21, 2024
Oncology, Professional Services, Health, Medical Devices, Legal, Other Health, General Health, Exact Sciences (company), Patent, Exact sciences, Collection, Science, Advertising, District court

This ruling paves the way for Exact Sciences to seek relief for Geneoscopy’s future infringement and false advertising.

Key Points: 
  • This ruling paves the way for Exact Sciences to seek relief for Geneoscopy’s future infringement and false advertising.
  • Exact Sciences filed the lawsuit in November 2023 to prevent Geneoscopy from infringing upon Exact Sciences’ intellectual property central to its Cologuard® colorectal cancer screening test and to put an end to Geneoscopy’s false and misleading advertising and promotion about the alleged clinical performance and superiority of ColoSense.
  • “Exact Sciences applauds the Court’s decision to permit our infringement and false advertising claims to proceed,” said Kevin Conroy, chairman and CEO of Exact Sciences.
  • Exact Sciences expects its new case to proceed on a similar schedule as the existing case, given the overlapping issues.

Exact Sciences Earns 2024 Great Place To Work® Certification™

Retrieved on: 
Mercoledì, Maggio 22, 2024
Oncology, Professional Services, Health, Human Resources, General Health, Research, Science, Certification, Trust, Cancer, Exact sciences, Organization, Workplace, Culture, Management

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2024 Great Place To Work® for the sixth consecutive year.

Key Points: 
  • Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2024 Great Place To Work® for the sixth consecutive year.
  • This year, 85% of employees called Exact Sciences a Great Place To Work, surpassing the average U.S. company by an impressive margin of 28 points.
  • “We’re honored that Exact Sciences is a certified Great Place To Work for the sixth year in a row,” said Sarah Condella, executive vice president of human resources at Exact Sciences.
  • “Great Place To Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience,” said Sarah Lewis-Kulin, vice president of global recognition at Great Place To Work.

Exact Sciences Announces First-Quarter 2024 Results

Retrieved on: 
Mercoledì, Maggio 8, 2024
Medical Devices, Health, Genetics, Medical Supplies, Oncology, Core, Net, Webcast, Exact sciences, Medicine, Patient, COVID-19, COVID-19 testing, Acquisition, Adjustment, GAAP, Video game

“The Exact Sciences team is off to a strong start again in 2024.

Key Points: 
  • “The Exact Sciences team is off to a strong start again in 2024.
  • The company has maintained its revenue guidance of $2.810-$2.850 billion during 2024, assuming:
    Screening revenue of $2.155-$2.175 billion, and
    Precision Oncology revenue of $655-$675 million.
  • Company management will host a conference call and webcast on Wednesday, May 8, 2024, at 5 p.m.
  • ET to discuss first-quarter 2024 results.

Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024

Retrieved on: 
Martedì, Maggio 7, 2024
General Health, Health, Oncology, Simulation, Colorectal cancer, Gastrointestinal disease, Risk, Large intestine, Abstract, AGAF, Cohort, Exact sciences, Threshold, Disease, Trial, Exact Sciences (company), Patient, MPH, Mortality, DDW, Cancer, Incidence, Vaccine

This includes data on Cologuard®, the best-in-class non-invasive screening test for colorectal cancer in patients 45 and older at average risk, and the next-generation Cologuard test in development, Cologuard Plus™.

Key Points: 
  • This includes data on Cologuard®, the best-in-class non-invasive screening test for colorectal cancer in patients 45 and older at average risk, and the next-generation Cologuard test in development, Cologuard Plus™.
  • “At Exact Sciences, we know colorectal cancer screening must be able to find and also help prevent the disease to positively impact patient outcomes, which is how the Cologuard test was designed,” said Paul Limburg, MD, MPH, AGAF, chief medical officer for screening, Exact Sciences.
  • Up to 40% of the screening-eligible population in the U.S. currently needs to be screened for colorectal cancer and our data at DDW can inform strategies to meaningfully address this critical gap.”1
    The following abstracts from Exact Sciences have been accepted for presentation at the annual meeting:
    Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
    Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
    Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
    Presentation Title: Estimated Average-risk Colorectal Cancer Screening-eligible Population In The U.S.
  • Presentation Title: Impact Of Racial Disparities In The Quality Of Colonoscopy Screening On Colorectal Cancer Incidence And Mortality: A Simulation Modeling Analysis

Exact Sciences to Participate in May Investor Conference

Retrieved on: 
Mercoledì, Maggio 1, 2024
General Health, Health, Oncology, Conference, Webcast

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

Key Points: 

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
BofA Securities Health Care Conference, Las Vegas

Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

Retrieved on: 
Lunedì, Aprile 15, 2024
Medical Devices, Medical Supplies, Hospitals, Practice Management, Other Health, Biotechnology, Managed Care, General Health, Health, Oncology, Baxter International, FP, Baxter, CFO, Cancer, Patient, Science, Growth, 3M, Exact sciences, Management

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024.

Key Points: 
  • Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024.
  • Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience.
  • At Baxter, Mr. Bloomer led corporate financial planning, reporting, and analytics (FP&A) as vice president.
  • “Aaron comes to us with significant global experience setting corporate strategy and driving growth and operational discipline from his leadership roles at incredible companies,” said Kevin Conroy, chairman and chief executive officer of Exact Sciences.

Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes

Retrieved on: 
Giovedì, Aprile 11, 2024
Health, Oncology, Medical Supplies, Debt-to-GDP ratio, Sale, Agreement, Retirement, Common stock, Finance Secretary (India), Note, Security (finance)

Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “Agreements”) with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the “Existing Notes”).

Key Points: 
  • Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “Agreements”) with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the “Existing Notes”).
  • The closing of the transaction is expected to occur on April 17, 2024, subject to customary closing conditions.
  • The New Notes will mature on April 15, 2031 (the “Maturity Date”), unless earlier repurchased, redeemed or converted.
  • K&L Gates LLP represented Exact Sciences Corporation and Kramer Levin Naftalis & Frankel LLP represented the placement agent in the transaction.

Exact Sciences Schedules First Quarter 2024 Earnings Call

Retrieved on: 
Lunedì, Aprile 8, 2024
General Health, Health, Oncology, Medical Supplies, Webcast

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024.

Key Points: 
  • Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024.
  • Following the release, company management will host a webcast and conference call at 5 p.m.
  • ET to discuss financial results and business progress.